Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Cadrenal Therapeutics, Inc. Common Stock(CVKD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CVKD
10/23/2026: CVKD (1-star) is currently NOT-A-BUY. Pass it for now.
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company focused on developing tecarfarin, an oral anticoagulant for patients with end-stage renal disease. The company's main strength lies in its targeted approach to a specific, high-need patient population that is often underserved by current therapies. Its primary growth opportunity rests on the successful clinical and regulatory validation of tecarfarin. However, the company faces significant execution and competition risks, given it has no revenue and must compete with established pharmaceutical giants. This stock may suit speculative investors comfortable with high volatility and long-term biotech development timelines, while they should monitor clinical milestones and capital funding updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers speculative growth potential tied to clinical binary outcomes but lacks the revenue growth typical of mature growth stocks. |
| Momentum investor | Mixed fit | Momentum may be driven by news cycles related to clinical trials, requiring active monitoring for favorable technical or fundamental catalysts. |
| Value investor | Weak fit | The lack of earnings and assets makes traditional value metrics like P/E or P/B inapplicable. |
| Dividend investor | Weak fit | The company is in a capital-intensive development phase and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and clinical risk profile are unsuitable for conservative, risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings based on clinical trial news and capital market sentiment. |
| Valuation risk | High | Valuation is highly speculative and based on the potential success of a single pipeline asset. |
| Competition risk (Anticoagulation market) | High | The market is dominated by well-entrenched pharmaceutical giants with vast marketing and R&D budgets. |
| Business quality | Medium / high | The business relies entirely on the success of a single drug candidate, limiting operational diversity. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | The company must successfully navigate complex FDA regulatory pathways to achieve commercialization. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 178.84% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.42M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 173.3K shares | Beta 1.95 | 52 Weeks Range 0.82 - 14.18 | Updated Date 10/23/2026 |
52 Weeks Range 0.82 - 14.18 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.91 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical stage R&D for tecarfarin. | The company is currently spending money to develop a drug and does not yet earn money from sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24.68M | Price to Sales(TTM) - |
Enterprise Value 24.68M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 3.57M | Shares Floating 3.22M |
Shares Outstanding 3.57M | Shares Floating 3.22M | ||
Percent Insiders 9.66 | Percent Institutions 10.35 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.